Tumor necrosis factor receptors encoded by poxviruses

Molecular Genetics and Metabolism

Volumn 67, Issue 4, 1999, Pages 278-282

  Cunnion, Kenji M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cowpox virus; Tumor necrosis factor receptor

Indexed keywords

MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL MODEL; APOPTOSIS; AUTOIMMUNE DISEASE; CROHN DISEASE; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LIGAND BINDING; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; RABBIT; RHEUMATOID ARTHRITIS; SHORT SURVEY; VIRUS INFECTION;

ANIMALIA; COWPOX VIRUS; DNA VIRUSES; MYXOMA VIRUS; ORYCTOLAGUS CUNICULUS; POXVIRIDAE;

EID: 0032866454     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.1999.2878     Document Type: Article

References (48)

1. Smith R A, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem. 262:1987;6951-6954.
2. Jones E Y, Stuart D I, Walker N P. Structure of tumor necrosis factor. Nature. 338:1989;225-228.
3. Dinarello C A, Cannon J G, Wolff S M, Bernheim H A, Beutler B, Cerami A, Figari I S, Palladino M A Jr, O'Connor J V. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 163:1986;1433-1450.
4. Gamble J R, Harlan J M, Klebanoff S J, Vadas M A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA. 82:1985;8667-8671.
5. Tsujimoto M, Yokota S, Vilcek J, Weissman G. Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun. 137:1985;1094-1100.
6. Klebaboff S J, Vadas M A, Harlan J M, Sparks L J, Gamble J R, Agosti J M, Waltersdorph A M. Stimulation of neutrophils by tumor necrosis factor. J Immunol. 36:1986;4220-4225.
7. Moser R B, Schleiffenbaum B, Groscurth P, Fehr J. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest. 83:1989;444-455.
8. Nawroth P P, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 163:1986;1363-1375.
9. Beutler B. Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. 1992;Raven Press, New York.
10. Marsters S A, Frutkin A D, Simpson N J, Fendly B M, Ashkenazi A. Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. J Biol Chem. 267:1992;5747-5750.
11. Grell M. Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. J Inflamm. 47:1996;8-17.
12. Carswell E A, Old L J, Kassel R L, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Prod Natl Acad Sci USA. 72:1975;3666-3670.
13. Fisch H, Gifford G E. In vitro production of rabbit macrophage tumor cell cytotoxin. Int J Cancer. 32:1983;105-112.
14. Ware C F, Crowe P D, Grayson M H, Androlewicz M J, Browning J L. Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol. 149:1992;3381-3388.
15. Arend W P, Dayer J M. Inhibition of the production and effects of interleukin 1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 33:1995;1449-1461.
16. Baert F J, D'Haens G R, Peeters M, Hiele M I, Schaible T F, Shealy D, Geboes K, Rutgeerts P J. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 116:1999;22-28.
17. Sean Riminton D, Korner H, Strickland D H, Lemckert F A, Pollard J D, Sedgwick J D. Challenging cytokine redundancy: Inflammatory cell movement and clinical course of experimental autoimmune encephalitis are normal in lymphotoxin-deficient, but not tumor necrosis factor deficient, mice. J Exp Med. 187:1998;1517-1528.
18. Kubota T, McTiernan C F, Frye C S, Demetris A J, Feldman A M. Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Cardiac Failure. 3:1997;117-124.
19. Beutler B, Milsark I W, Cerami A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science. 229:1985;869-871.
20. Xu J, Zhong N S. The interaction of tumor necrosis factor alpha and endothelin-1 in pathogenic models of asthma. Clin Exp Allergy. 27:1997;568-573.
21. Cooke K R, Hill G R, Crawford J M, Bungard D, Brinson Y S, Delmonte J Jr, Ferrara J L. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 102:1998;1882-1891.
22. Bertolini D R, Nedwin G E, Bringman T S, Smith D D, Mundy G R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature. 319:1986;516-518.
23. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 334:1996;1717-1725.
24. Englemann H, Holtmann H, Brakebusch C, Avni Y S, Sarov I, Nophar Y, Hadas E, Leitner O, Wallach D. Antibodies to a soluble form of human tumor necrosis factor receptor have TNF-like activity. J Biol Chem. 265:1990;14497-14504.
25. Tartaglia L A, Goeddel D V, Reynolds C, Figari I S, Weber R F, Fendly B M, Palladino M A Jr. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol. 151:1993;4637-4641.
26. Banner D W, D'Arcy A, Janes W, Gentz R, Schoenfeld H J, Broger C, Loetscher H, Lesslauer W. Crystal structure of the soluble human 55kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell. 73:1993;431-445.
27. Tartaglia L A, Ayres T M, Wong G H, Goeddel D V. A novel domain within the 55kd TNF receptor signals death. Cell. 74:1993;845-853.
28. Koni P A, Flavell R A. A role for tumor necrosis factor type I in gut-associated lymphoid tissue development: Genetic evidence of synergism with lymphotoxin beta. J Exp Med. 187:1998;1977-1983.
29. Abe Y, Osuka Y, Nakata T, Kashu Y, Kimura S. The functional role of 55- and 75-kDa tumor necrosis factor receptors in human polymorphonuclear cells in vitro. Cytokine. 7:1995;39-49.
30. Mason A T, McVicar D W, Smith C A, Young H A, Ware C F, Ortaldo J R. Regulation of NK cells through the 80-kDa TNFR (CD120b). J Leukocyte Biol. 58:1995;249-255.
31. Darnay B G, Aggarwal B B. Early events in TNF signaling: A story of associations and dissociations. J Leukocyte Biol. 61:1997;559-566.
32. Crowe P D, Walter B N, Mohler K M, Otten-Evans C, Black R A, Ware C F. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med. 181:1995;1205-1210.
33. Bjornberg F, Lantz M, Gullberg U. Metaloproteases and serineproteases are involved in the cleavage of the two tumor necrosis factor (TNF) receptors to soluble forms in the myeloid cell lines U-937 and THP-1. Scand J Immunol. 42:1995;418-424.
34. Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer J M, Vischer T, Yazici H, Guerne P A. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol. 24:1997;303-308.
35. Tracey K J, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 9:1993;317-343.
36. Mohler K M, Torrance D S, Smith C A, Goodwin R G, Stremler K E, Fung V P, Madani H, Widmer M B. Soluble tumor necrosis factor receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 151:1993;1548-1561.
37. Nam M H, Reda D, Boujoukos A J, Agosti J, Suffredini A F. Recombinant human dimeric tumor necrosis factor receptor (TNFR:Fc): Safety and pharmacokinetics in human volunteers. Clin Res. 41:1993;249A.
38. Moreland L W, Baumgartner S W, Schiff M H, Tindall E A, Fleischmann R M, Weaver A L, Ettlinger R E, Cohen S, Koopman W J, Mohler K, Widmer M B, Blosch C M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) - Fc fusion protein. N Engl J Med. 337:1997;141-147.
39. Smith C A, Davis T, Anderson D, Solam L, Beckmann M P, Jerzy R, Dower S K, Cosman D, Goodwin R G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 248:1990;1019-1023.
40. Hu F Q, Smith C A, Pickup D J. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology. 204:1994;343-356.
41. Smith C A, Hu F Q, Smith T D, Richards C L, Smolak P, Goodwin R G, Pickup D J. Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT alpha. Virology. 223:1996;132-147.
42. Loparev V N, Parsons J M, Knight J C, Panus J F, Ray C A, Buller R ML, Pickup D J. A third distinct tumor necrosis factor receptor of orthopoxviruses. Proc Natl Acad Sci USA. 95:1998;3786-3791.
43. Sedger L, McFadden G. M-T2: A poxvirus TNF receptor homologue with dual activities. Immunol Cell Biol. 74:1996;538-545.
44. McFadden G, Schreiber M, Sedger L. Myxoma T2 protein as a model for poxvirus TNF receptor homologues. J Neuroimmunol. 72:1997;119-126.
45. Schreiber M, Rajarathnam K, McFadden G. Myxoma virus T2 protein, a tumor necrosis factor receptor homologue, is secreted as a monomer and dimer that each bind rabbit TNF alpha, but the dimer is the more potent TNF inhibitor. J Biol Chem. 271:1996;13333-13341.
46. Upton C, Macen J L, Schreiber M, McFadden G. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor gene family that contributes to the viral virulence. Virology. 184:1991;370-382.
47. Macen J L, Graham K A, Lee S F, Schreiber M, Bashkov L K, McFadden G. Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected T lymphocytes. Virology. 218:1996;232-237.
48. Schreiber, M, Sedger, L, McFadden, G. Distinct domains of M-T2, the myxoma virus tumor necrosis factor receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. J Virol71:2171-2181.